[{"query_translation":"\"1 palmitoyl 2 oleoyl sn glycero 3 phospho rac 1 glycerol\"[Title/Abstract]","search_time":"2025-06-29T09:09:34.09","drug_name":"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adsorption"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["drug effects"],"descriptor":"Bacterial Adhesion"},{"qualifiers":["drug effects"],"descriptor":"Cell Adhesion"},{"qualifiers":[],"descriptor":"Cell Line"},{"qualifiers":["administration &amp; dosage","chemistry"],"descriptor":"Coated Materials, Biocompatible"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Materials Testing"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":["drug effects"],"descriptor":"Osteoblasts"},{"qualifiers":["chemistry","pharmacology"],"descriptor":"Phospholipids"},{"qualifiers":[],"descriptor":"Prostheses and Implants"},{"qualifiers":[],"descriptor":"Surface Properties"}],"pmid":"17323171","title":"Phospholipids as implant coatings."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["chemistry","pharmacology"],"descriptor":"Anti-Infective Agents"},{"qualifiers":["chemistry","pharmacology"],"descriptor":"Antimicrobial Cationic Peptides"},{"qualifiers":[],"descriptor":"Anura"},{"qualifiers":[],"descriptor":"Benzothiazoles"},{"qualifiers":[],"descriptor":"Carbocyanines"},{"qualifiers":["chemistry","drug effects"],"descriptor":"Cell Membrane"},{"qualifiers":["drug effects"],"descriptor":"Cell Membrane Permeability"},{"qualifiers":["chemistry"],"descriptor":"Dimyristoylphosphatidylcholine"},{"qualifiers":[],"descriptor":"Fluoresceins"},{"qualifiers":["pharmacology"],"descriptor":"Gramicidin"},{"qualifiers":[],"descriptor":"Lipid Bilayers"},{"qualifiers":[],"descriptor":"Membrane Potentials"},{"qualifiers":["chemistry"],"descriptor":"Phosphatidylcholines"},{"qualifiers":["chemistry"],"descriptor":"Phosphatidylglycerols"},{"qualifiers":[],"descriptor":"Protein Structure, Secondary"},{"qualifiers":[],"descriptor":"Staphylococcus aureus"}],"pmid":"19167304","title":"Effect of membrane composition on antimicrobial peptides aurein 2.2 and 2.3 from Australian southern bell frogs."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adsorption"},{"qualifiers":[],"descriptor":"Air"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Cattle"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Infant, Newborn"},{"qualifiers":[],"descriptor":"Mass Spectrometry"},{"qualifiers":["chemistry"],"descriptor":"Membrane Proteins"},{"qualifiers":[],"descriptor":"Membranes, Artificial"},{"qualifiers":[],"descriptor":"Microscopy, Fluorescence"},{"qualifiers":[],"descriptor":"Phosphatidylglycerols"},{"qualifiers":["chemistry"],"descriptor":"Proteolipids"},{"qualifiers":["physiology"],"descriptor":"Pulmonary Alveoli"},{"qualifiers":["chemistry"],"descriptor":"Pulmonary Surfactants"},{"qualifiers":["physiopathology"],"descriptor":"Respiratory Distress Syndrome, Newborn"},{"qualifiers":[],"descriptor":"Surface Tension"},{"qualifiers":[],"descriptor":"Water"}],"pmid":"10600889","title":"SP-B refining of pulmonary surfactant phospholipid films."},{"mesh_descriptors":[{"qualifiers":["chemistry","metabolism","pharmacology"],"descriptor":"Antimicrobial Cationic Peptides"},{"qualifiers":["methods"],"descriptor":"Calorimetry"},{"qualifiers":["drug effects","metabolism"],"descriptor":"Cell Membrane"},{"qualifiers":["drug effects"],"descriptor":"Escherichia coli"},{"qualifiers":["metabolism"],"descriptor":"Fluoresceins"},{"qualifiers":["metabolism"],"descriptor":"Lipid Bilayers"},{"qualifiers":["metabolism"],"descriptor":"Liposomes"},{"qualifiers":[],"descriptor":"Magnetic Resonance Spectroscopy"},{"qualifiers":[],"descriptor":"Microbial Sensitivity Tests"},{"qualifiers":[],"descriptor":"Microscopy, Confocal"},{"qualifiers":[],"descriptor":"Models, Molecular"},{"qualifiers":["metabolism"],"descriptor":"Phospholipids"},{"qualifiers":[],"descriptor":"Protein Conformation"},{"qualifiers":[],"descriptor":"Spectrometry, Fluorescence"},{"qualifiers":["drug effects"],"descriptor":"Staphylococcus aureus"},{"qualifiers":[],"descriptor":"Titrimetry"}],"pmid":"15853943","title":"Interactions of the antimicrobial peptide Ac-FRWWHR-NH(2) with model membrane systems and bacterial cells."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Amino Acid Sequence"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Cattle"},{"qualifiers":[],"descriptor":"Chromatography, Affinity"},{"qualifiers":[],"descriptor":"Enzyme Stability"},{"qualifiers":["chemistry","genetics","isolation &amp; purification"],"descriptor":"Fungal Proteins"},{"qualifiers":["enzymology","genetics"],"descriptor":"Fungi"},{"qualifiers":["chemistry","genetics","isolation &amp; purification"],"descriptor":"Mitochondrial Proton-Translocating ATPases"},{"qualifiers":[],"descriptor":"Molecular Sequence Data"},{"qualifiers":["enzymology","genetics"],"descriptor":"Pichia"},{"qualifiers":[],"descriptor":"Protein Structure, Tertiary"},{"qualifiers":[],"descriptor":"Protein Subunits"},{"qualifiers":["enzymology","genetics"],"descriptor":"Saccharomyces cerevisiae"},{"qualifiers":["chemistry","genetics","isolation &amp; purification"],"descriptor":"Saccharomyces cerevisiae Proteins"},{"qualifiers":[],"descriptor":"Sequence Homology, Amino Acid"},{"qualifiers":[],"descriptor":"Species Specificity"},{"qualifiers":["enzymology","genetics"],"descriptor":"Yarrowia"}],"pmid":"25759169","title":"The purification and characterization of ATP synthase complexes from the mitochondria of four fungal species."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Anti-Infective Agents"},{"qualifiers":[],"descriptor":"Bacteria"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Lipid Bilayers"},{"qualifiers":[],"descriptor":"Molecular Dynamics Simulation"},{"qualifiers":[],"descriptor":"Phospholipids"},{"qualifiers":[],"descriptor":"Pore Forming Cytotoxic Proteins"}],"pmid":"33839361","title":"Antimicrobial peptide induced colloidal transformations in bacteria-mimetic vesicles: Combining in silico tools and experimental methods."},{"mesh_descriptors":[{"qualifiers":["chemistry"],"descriptor":"Lipid Bilayers"},{"qualifiers":["chemistry"],"descriptor":"Membrane Lipids"},{"qualifiers":[],"descriptor":"Membrane Potentials"},{"qualifiers":[],"descriptor":"Molecular Dynamics Simulation"},{"qualifiers":["chemistry"],"descriptor":"Phosphatidylcholines"},{"qualifiers":["chemistry"],"descriptor":"Spider Venoms"}],"pmid":"28597209","title":"Molecular Dynamics Simulation Reveals Unique Interplays Between a Tarantula Toxin and Lipid Membranes."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Alkylation"},{"qualifiers":["chemical synthesis","chemistry"],"descriptor":"Amino Acids"},{"qualifiers":[],"descriptor":"Hydrogen-Ion Concentration"},{"qualifiers":[],"descriptor":"Hydrophobic and Hydrophilic Interactions"},{"qualifiers":["chemistry"],"descriptor":"Lipids"},{"qualifiers":[],"descriptor":"Molecular Structure"},{"qualifiers":["chemistry"],"descriptor":"Phosphatidylcholines"},{"qualifiers":["chemistry"],"descriptor":"Phosphatidylglycerols"},{"qualifiers":[],"descriptor":"Sensitivity and Specificity"}],"pmid":"18205118","title":"pH-sensitive vesicles containing a lipidic beta-amino acid with two hydrophobic chains."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Amino Acid Sequence"},{"qualifiers":["chemistry"],"descriptor":"Antimicrobial Cationic Peptides"},{"qualifiers":[],"descriptor":"Kinetics"},{"qualifiers":[],"descriptor":"Lipid Bilayers"},{"qualifiers":[],"descriptor":"Membranes, Artificial"},{"qualifiers":[],"descriptor":"Molecular Sequence Data"},{"qualifiers":["methods"],"descriptor":"Spectrum Analysis"}],"pmid":"21595453","title":"Membrane orientation of MSI-78 measured by sum frequency generation vibrational spectroscopy."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Amino Acid Sequence"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["chemistry","metabolism","pharmacology"],"descriptor":"Anti-Infective Agents"},{"qualifiers":["chemistry","genetics","metabolism","pharmacology"],"descriptor":"Antimicrobial Cationic Peptides"},{"qualifiers":[],"descriptor":"Computer Simulation"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["chemistry"],"descriptor":"Lipid Bilayers"},{"qualifiers":[],"descriptor":"Micelles"},{"qualifiers":[],"descriptor":"Microbial Sensitivity Tests"},{"qualifiers":[],"descriptor":"Models, Molecular"},{"qualifiers":[],"descriptor":"Molecular Sequence Data"},{"qualifiers":[],"descriptor":"Molecular Structure"},{"qualifiers":[],"descriptor":"Nuclear Magnetic Resonance, Biomolecular"},{"qualifiers":["chemistry","genetics","metabolism","pharmacology"],"descriptor":"Peptides"},{"qualifiers":[],"descriptor":"Protein Conformation"},{"qualifiers":["drug effects"],"descriptor":"Pseudomonas aeruginosa"},{"qualifiers":["chemistry","genetics","metabolism","pharmacology"],"descriptor":"beta-Defensins"}],"pmid":"19580334","title":"Structure-dependent charge density as a determinant of antimicrobial activity of peptide analogues of defensin."}],"translation_set":[],"indication":"Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin which was indicated for the prevention of respiratory distress syndrome in premature infants.","status":"success","count":28,"disease_analysis":{"summary":{"unique_diseases_found":1,"matched_diseases":["Respiratory Distress Syndrome, Newborn"],"diseases_with_associations":1,"total_mesh_terms":126,"total_publications_analyzed":10},"disease_associations":{"Respiratory Distress Syndrome, Newborn":[{"pmid":"10600889","title":"SP-B refining of pulmonary surfactant phospholipid films.","qualifiers":["physiopathology"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%221-Palmitoyl-2-oleoyl-sn-glycero-3-%28phospho-rac-%281-glycerol%29%29%22%5BTIAB%5D%20OR%20%221-Palmitoyl-2-oleoyl-sn-glycero-3-%28phospho-rac-%281-glycerol%29%29%22%5BMeSH%20Terms%5D","original_query":"\"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[TIAB] OR \"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[MeSH Terms]","retmax":10,"query":"\"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[TIAB] OR \"1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))\"[MeSH Terms]","pmids":["17323171","19167304","10600889","15853943","25759169","33839361","28597209","18205118","21595453","19580334"]},{"query_translation":"\"2 2 dibenzothiazyl disulfide\"[Title/Abstract]","search_time":"2025-06-29T09:09:34.77","drug_name":"2,2'-Dibenzothiazyl disulfide","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Benzothiazoles"},{"qualifiers":["metabolism"],"descriptor":"Bile"},{"qualifiers":["blood","pharmacokinetics"],"descriptor":"Carbon Radioisotopes"},{"qualifiers":["chemistry"],"descriptor":"Feces"},{"qualifiers":["metabolism"],"descriptor":"Gastric Mucosa"},{"qualifiers":[],"descriptor":"Intestinal Absorption"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Rats"},{"qualifiers":[],"descriptor":"Rats, Wistar"},{"qualifiers":["blood","pharmacokinetics","urine"],"descriptor":"Thiazoles"}],"pmid":"8750898","title":"Metabolism of 2-thiobenzothiazoles in the rat. Urinary, fecal and biliary metabolites of 2-benzothiazyl sulfenamides."}],"translation_set":[],"indication":"2,2'-Dibenzothiazyl disulfide is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.","status":"success","count":1,"disease_analysis":{"summary":{"unique_diseases_found":0,"matched_diseases":[],"diseases_with_associations":0,"total_mesh_terms":11,"total_publications_analyzed":1},"disease_associations":{}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%222%2C2%27-Dibenzothiazyl%20disulfide%22%5BTIAB%5D%20OR%20%222%2C2%27-Dibenzothiazyl%20disulfide%22%5BMeSH%20Terms%5D","original_query":"\"2,2'-Dibenzothiazyl disulfide\"[TIAB] OR \"2,2'-Dibenzothiazyl disulfide\"[MeSH Terms]","retmax":1,"query":"\"2,2'-Dibenzothiazyl disulfide\"[TIAB] OR \"2,2'-Dibenzothiazyl disulfide\"[MeSH Terms]","pmids":["8750898"]},{"query_translation":"\"4 isopropylamino diphenylamine\"[Title/Abstract]","search_time":"2025-06-29T09:09:35.401","drug_name":"4-(Isopropylamino)diphenylamine","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["diagnosis","etiology"],"descriptor":"Dermatitis, Allergic Contact"},{"qualifiers":["diagnosis","etiology"],"descriptor":"Dermatitis, Occupational"},{"qualifiers":["adverse effects"],"descriptor":"Phenylenediamines"},{"qualifiers":[],"descriptor":"Rubber"},{"qualifiers":[],"descriptor":"Patch Tests"}],"pmid":"37015229","title":"N-isopropyl-N'-phenylenediamine (IPPD): An unusual case of professional facial allergic contact dermatitis."}],"translation_set":[],"indication":"4-(Isopropylamino)diphenylamine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.","status":"success","count":1,"disease_analysis":{"summary":{"unique_diseases_found":2,"matched_diseases":["Dermatitis, Allergic Contact","Dermatitis, Occupational"],"diseases_with_associations":2,"total_mesh_terms":6,"total_publications_analyzed":1},"disease_associations":{"Dermatitis, Allergic Contact":[{"pmid":"37015229","title":"N-isopropyl-N'-phenylenediamine (IPPD): An unusual case of professional facial allergic contact dermatitis.","qualifiers":["diagnosis","etiology"]}],"Dermatitis, Occupational":[{"pmid":"37015229","title":"N-isopropyl-N'-phenylenediamine (IPPD): An unusual case of professional facial allergic contact dermatitis.","qualifiers":["diagnosis","etiology"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%224-%28Isopropylamino%29diphenylamine%22%5BTIAB%5D%20OR%20%224-%28Isopropylamino%29diphenylamine%22%5BMeSH%20Terms%5D","original_query":"\"4-(Isopropylamino)diphenylamine\"[TIAB] OR \"4-(Isopropylamino)diphenylamine\"[MeSH Terms]","retmax":1,"query":"\"4-(Isopropylamino)diphenylamine\"[TIAB] OR \"4-(Isopropylamino)diphenylamine\"[MeSH Terms]","pmids":["37015229"]},{"query_translation":"\"Abacavir\"[Title/Abstract]","search_time":"2025-06-29T09:09:36.058","drug_name":"Abacavir","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":["adverse effects","pharmacokinetics","therapeutic use"],"descriptor":"Anti-HIV Agents"},{"qualifiers":[],"descriptor":"Clinical Trials as Topic"},{"qualifiers":["adverse effects","pharmacokinetics","therapeutic use"],"descriptor":"Dideoxynucleosides"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects","pharmacokinetics","therapeutic use"],"descriptor":"Reverse Transcriptase Inhibitors"}],"pmid":"9585869","title":"Abacavir."},{"mesh_descriptors":[{"qualifiers":["genetics"],"descriptor":"Black People"},{"qualifiers":["adverse effects"],"descriptor":"Dideoxynucleosides"},{"qualifiers":["diagnosis","ethnology","genetics"],"descriptor":"Drug Hypersensitivity"},{"qualifiers":[],"descriptor":"Genetic Testing"},{"qualifiers":[],"descriptor":"Genotype"},{"qualifiers":["drug therapy","ethnology","immunology"],"descriptor":"HIV Infections"},{"qualifiers":["genetics"],"descriptor":"HLA-B Antigens"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects"],"descriptor":"Reverse Transcriptase Inhibitors"}],"pmid":"18536095","title":"Abacavir hypersensitivity."},{"mesh_descriptors":[{"qualifiers":["adverse effects"],"descriptor":"Anti-HIV Agents"},{"qualifiers":["epidemiology","etiology"],"descriptor":"Cardiovascular Diseases"},{"qualifiers":[],"descriptor":"Clinical Trials as Topic"},{"qualifiers":["adverse effects"],"descriptor":"Dideoxynucleosides"},{"qualifiers":["complications","drug therapy"],"descriptor":"HIV Infections"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Meta-Analysis as Topic"},{"qualifiers":["epidemiology","etiology"],"descriptor":"Myocardial Infarction"},{"qualifiers":[],"descriptor":"Risk"}],"pmid":"27260856","title":"Abacavir and cardiovascular disease: A critical look at the data."},{"mesh_descriptors":[{"qualifiers":["therapeutic use"],"descriptor":"Dideoxynucleosides"},{"qualifiers":[],"descriptor":"Drug Combinations"},{"qualifiers":["drug therapy"],"descriptor":"HIV Infections"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Lamivudine"},{"qualifiers":["therapeutic use"],"descriptor":"Reverse Transcriptase Inhibitors"},{"qualifiers":["therapeutic use"],"descriptor":"Tenofovir"},{"qualifiers":["therapeutic use"],"descriptor":"Zidovudine"}],"pmid":"30730651","title":"Zidovudine, tenofovir or abacavir? Different adverse effect profiles."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":["adverse effects"],"descriptor":"Anti-HIV Agents"},{"qualifiers":["adverse effects"],"descriptor":"Antiretroviral Therapy, Highly Active"},{"qualifiers":["etiology"],"descriptor":"Chemical and Drug Induced Liver Injury"},{"qualifiers":["adverse effects"],"descriptor":"Dideoxynucleosides"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["drug therapy"],"descriptor":"HIV Infections"},{"qualifiers":["immunology"],"descriptor":"HLA-B Antigens"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Retrospective Studies"},{"qualifiers":[],"descriptor":"Risk Factors"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"27054757","title":"Abacavir-induced liver toxicity."},{"mesh_descriptors":[{"qualifiers":["adverse effects","classification"],"descriptor":"Antiviral Agents"},{"qualifiers":[],"descriptor":"Disease Management"},{"qualifiers":["diagnosis","etiology","therapy"],"descriptor":"Drug Hypersensitivity"},{"qualifiers":[],"descriptor":"Humans"}],"pmid":"25017682","title":"Antiviral drug allergy."}],"translation_set":[],"indication":"Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection.[L30400] It is available in a combination product alongside [dolutegravir] and [lamivudine] for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.[L41365]","status":"success","count":2532,"disease_analysis":{"summary":{"unique_diseases_found":5,"matched_diseases":["Cardiovascular Diseases","HIV Infections","Myocardial Infarction","Drug Hypersensitivity","Chemical and Drug Induced Liver Injury"],"diseases_with_associations":5,"total_mesh_terms":47,"total_publications_analyzed":6},"disease_associations":{"Cardiovascular Diseases":[{"pmid":"27260856","title":"Abacavir and cardiovascular disease: A critical look at the data.","qualifiers":["epidemiology","etiology"]}],"HIV Infections":[{"pmid":"18536095","title":"Abacavir hypersensitivity.","qualifiers":["drug therapy","ethnology","immunology"]},{"pmid":"27260856","title":"Abacavir and cardiovascular disease: A critical look at the data.","qualifiers":["complications","drug therapy"]},{"pmid":"30730651","title":"Zidovudine, tenofovir or abacavir? Different adverse effect profiles.","qualifiers":["drug therapy"]},{"pmid":"27054757","title":"Abacavir-induced liver toxicity.","qualifiers":["drug therapy"]}],"Myocardial Infarction":[{"pmid":"27260856","title":"Abacavir and cardiovascular disease: A critical look at the data.","qualifiers":["epidemiology","etiology"]}],"Drug Hypersensitivity":[{"pmid":"18536095","title":"Abacavir hypersensitivity.","qualifiers":["diagnosis","ethnology","genetics"]},{"pmid":"25017682","title":"Antiviral drug allergy.","qualifiers":["diagnosis","etiology","therapy"]}],"Chemical and Drug Induced Liver Injury":[{"pmid":"27054757","title":"Abacavir-induced liver toxicity.","qualifiers":["etiology"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abacavir%22%5BTIAB%5D%20OR%20%22Abacavir%22%5BMeSH%20Terms%5D","original_query":"\"Abacavir\"[TIAB] OR \"Abacavir\"[MeSH Terms]","retmax":10,"query":"\"Abacavir\"[TIAB] OR \"Abacavir\"[MeSH Terms]","pmids":["9585869","30000607","30725802","32809632","31643550","18536095","27260856","30730651","27054757","25017682"]},{"query_translation":"\"Abaloparatide\"[Title/Abstract]","search_time":"2025-06-29T09:09:36.721","drug_name":"Abaloparatide","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Bone Density"},{"qualifiers":["pharmacology"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":["therapeutic use"],"descriptor":"Calcium"},{"qualifiers":["therapeutic use"],"descriptor":"Diphosphonates"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["complications","diagnosis","drug therapy"],"descriptor":"Osteoporosis"},{"qualifiers":["drug therapy"],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":["complications","prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":["therapeutic use"],"descriptor":"Vitamin D"}],"pmid":"35478046","title":"The clinician's guide to prevention and treatment of osteoporosis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["adverse effects"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":["adverse effects"],"descriptor":"Teriparatide"},{"qualifiers":["adverse effects"],"descriptor":"Alendronate"},{"qualifiers":["complications","drug therapy"],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":["adverse effects"],"descriptor":"Denosumab"},{"qualifiers":["prevention &amp; control"],"descriptor":"Fractures, Bone"},{"qualifiers":["complications","drug therapy"],"descriptor":"Osteoporosis"},{"qualifiers":["adverse effects"],"descriptor":"Diphosphonates"},{"qualifiers":["prevention &amp; control"],"descriptor":"Spinal Fractures"},{"qualifiers":[],"descriptor":"Physicians"}],"pmid":"36592455","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["pharmacology"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["methods"],"descriptor":"Geriatric Assessment"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["therapy"],"descriptor":"Osteoporosis"},{"qualifiers":["therapy"],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":["prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":[],"descriptor":"Risk Factors"}],"pmid":"32773051","title":"Osteoporosis in Older Adults."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Bone Density"},{"qualifiers":["therapeutic use"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":["therapeutic use"],"descriptor":"Denosumab"},{"qualifiers":["therapeutic use"],"descriptor":"Diphosphonates"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["drug therapy","epidemiology","physiopathology"],"descriptor":"Osteoporosis"},{"qualifiers":["prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":["therapeutic use"],"descriptor":"Parathyroid Hormone-Related Protein"},{"qualifiers":[],"descriptor":"Risk Factors"},{"qualifiers":["therapeutic use"],"descriptor":"Teriparatide"}],"pmid":"30696576","title":"Osteoporosis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["drug effects"],"descriptor":"Bone Density"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["diagnostic imaging","physiology"],"descriptor":"Femur Neck"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["chemically induced"],"descriptor":"Hypercalcemia"},{"qualifiers":[],"descriptor":"Injections, Subcutaneous"},{"qualifiers":["injuries","physiopathology"],"descriptor":"Lumbar Vertebrae"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":["prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Parathyroid Hormone-Related Protein"},{"qualifiers":["drug effects","physiology"],"descriptor":"Pelvic Bones"},{"qualifiers":["therapeutic use"],"descriptor":"Placebos"},{"qualifiers":[],"descriptor":"Postmenopause"},{"qualifiers":[],"descriptor":"Radiography"},{"qualifiers":["prevention &amp; control"],"descriptor":"Spinal Fractures"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Teriparatide"},{"qualifiers":["injuries"],"descriptor":"Thoracic Vertebrae"}],"pmid":"27533157","title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Bone Density"},{"qualifiers":["therapeutic use"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":["therapeutic use"],"descriptor":"Denosumab"},{"qualifiers":["therapeutic use"],"descriptor":"Diphosphonates"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy"],"descriptor":"Osteoporosis"},{"qualifiers":["drug therapy"],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":["therapeutic use"],"descriptor":"Teriparatide"}],"pmid":"35279261","title":"Drug therapy for osteoporosis in older adults."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Alendronate"},{"qualifiers":["drug effects","physiology"],"descriptor":"Bone Density"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":["adverse effects","methods"],"descriptor":"Drug Therapy, Combination"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["diagnostic imaging","drug effects","physiopathology"],"descriptor":"Femur Neck"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["diagnostic imaging","drug effects","physiopathology"],"descriptor":"Lumbar Vertebrae"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["complications","diagnosis","drug therapy","physiopathology"],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":["diagnosis","epidemiology","etiology","prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Parathyroid Hormone-Related Protein"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Placebos"},{"qualifiers":[],"descriptor":"Radiography"},{"qualifiers":[],"descriptor":"Risk Factors"},{"qualifiers":["diagnosis","epidemiology","etiology","prevention &amp; control"],"descriptor":"Spinal Fractures"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"31674644","title":"Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy"],"descriptor":"Osteoporosis"},{"qualifiers":["therapeutic use"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":["drug effects"],"descriptor":"Bone Density"},{"qualifiers":["prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":["therapeutic use"],"descriptor":"Anabolic Agents"},{"qualifiers":["therapeutic use"],"descriptor":"Teriparatide"},{"qualifiers":[],"descriptor":"Cost-Benefit Analysis"}],"pmid":"39120740","title":"Recommendations for the optimal use of bone forming agents in osteoporosis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["adverse effects"],"descriptor":"Bone Density Conservation Agents"},{"qualifiers":[],"descriptor":"Postmenopause"},{"qualifiers":["adverse effects"],"descriptor":"Denosumab"},{"qualifiers":[],"descriptor":"Receptor, Parathyroid Hormone, Type 1"},{"qualifiers":["drug therapy"],"descriptor":"Osteoporosis"},{"qualifiers":["prevention &amp; control"],"descriptor":"Osteoporotic Fractures"},{"qualifiers":["adverse effects"],"descriptor":"Diphosphonates"},{"qualifiers":[],"descriptor":"Spinal Fractures"},{"qualifiers":[],"descriptor":"Risk Reduction Behavior"},{"qualifiers":["complications","drug therapy"],"descriptor":"Osteoporosis, Postmenopausal"},{"qualifiers":[],"descriptor":"Randomized Controlled Trials as Topic"}],"pmid":"37130601","title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials."}],"translation_set":[],"indication":"Abaloparatide is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) [L740,L44737] or patients who have failed or are intolerant to other available osteoporosis therapy.[L740] In postmenopausal women with osteoporosis, abaloparatide reduces the risk of vertebral and nonvertebral fractures.[L740] Abaloparatide is also indicated to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy.[L740]","status":"success","count":328,"disease_analysis":{"summary":{"unique_diseases_found":3,"matched_diseases":["Osteoporosis, Postmenopausal","Osteoporosis","Hypercalcemia"],"diseases_with_associations":3,"total_mesh_terms":124,"total_publications_analyzed":9},"disease_associations":{"Osteoporosis, Postmenopausal":[{"pmid":"35478046","title":"The clinician's guide to prevention and treatment of osteoporosis.","qualifiers":["drug therapy"]},{"pmid":"36592455","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","qualifiers":["complications","drug therapy"]},{"pmid":"32773051","title":"Osteoporosis in Older Adults.","qualifiers":["therapy"]},{"pmid":"27533157","title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.","qualifiers":[]},{"pmid":"35279261","title":"Drug therapy for osteoporosis in older adults.","qualifiers":["drug therapy"]},{"pmid":"31674644","title":"Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.","qualifiers":["complications","diagnosis","drug therapy","physiopathology"]},{"pmid":"37130601","title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.","qualifiers":["complications","drug therapy"]}],"Osteoporosis":[{"pmid":"35478046","title":"The clinician's guide to prevention and treatment of osteoporosis.","qualifiers":["complications","diagnosis","drug therapy"]},{"pmid":"36592455","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","qualifiers":["complications","drug therapy"]},{"pmid":"32773051","title":"Osteoporosis in Older Adults.","qualifiers":["therapy"]},{"pmid":"30696576","title":"Osteoporosis.","qualifiers":["drug therapy","epidemiology","physiopathology"]},{"pmid":"35279261","title":"Drug therapy for osteoporosis in older adults.","qualifiers":["drug therapy"]},{"pmid":"39120740","title":"Recommendations for the optimal use of bone forming agents in osteoporosis.","qualifiers":["drug therapy"]},{"pmid":"37130601","title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.","qualifiers":["drug therapy"]}],"Hypercalcemia":[{"pmid":"27533157","title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.","qualifiers":["chemically induced"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abaloparatide%22%5BTIAB%5D%20OR%20%22Abaloparatide%22%5BMeSH%20Terms%5D","original_query":"\"Abaloparatide\"[TIAB] OR \"Abaloparatide\"[MeSH Terms]","retmax":10,"query":"\"Abaloparatide\"[TIAB] OR \"Abaloparatide\"[MeSH Terms]","pmids":["35478046","36592455","32773051","30696576","25905277","27533157","35279261","31674644","39120740","37130601"]},{"query_translation":"\"Abametapir\"[Title/Abstract]","search_time":"2025-06-29T09:09:37.378","drug_name":"Abametapir","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["drug therapy"],"descriptor":"Lice Infestations"},{"qualifiers":["drug effects"],"descriptor":"Pediculus"},{"qualifiers":["adverse effects","therapeutic use","administration &amp; dosage","pharmacology"],"descriptor":"Insecticides"},{"qualifiers":["drug therapy"],"descriptor":"Scalp Dermatoses"}],"pmid":"38905531","title":"Drugs for head lice."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Infant"},{"qualifiers":["adverse effects"],"descriptor":"Insecticides"},{"qualifiers":["drug therapy"],"descriptor":"Lice Infestations"},{"qualifiers":[],"descriptor":"Pediculus"},{"qualifiers":[],"descriptor":"Pharmaceutical Preparations"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"34157881","title":"Abametapir for the Treatment of Head Lice: A Drug Review."},{"mesh_descriptors":[],"pmid":"36552044","title":"Investigating the Antibacterial Properties of Prospective Scabicides."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Administration, Topical"},{"qualifiers":[],"descriptor":"Adolescent"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Child"},{"qualifiers":[],"descriptor":"Child, Preschool"},{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Follow-Up Studies"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Infant"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Insecticides"},{"qualifiers":["drug therapy"],"descriptor":"Lice Infestations"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["drug effects"],"descriptor":"Pediculus"},{"qualifiers":["drug therapy"],"descriptor":"Scalp Dermatoses"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":[],"descriptor":"Young Adult"}],"pmid":"29999197","title":"Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Dermatologic Agents"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Insecticides"},{"qualifiers":["drug therapy"],"descriptor":"Lice Infestations"},{"qualifiers":[],"descriptor":"Pediculus"}],"pmid":"35839355","title":"Abametapir 0.74% (Xeglyze) for the Treatment of Head Lice."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adolescent"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Bedbugs"},{"qualifiers":[],"descriptor":"Child"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Insecticides"},{"qualifiers":["diagnosis","drug therapy","epidemiology"],"descriptor":"Lice Infestations"},{"qualifiers":[],"descriptor":"Pediculus"},{"qualifiers":["diagnosis","drug therapy","epidemiology"],"descriptor":"Scabies"}],"pmid":"34074914","title":"Common pediatric infestations: update on diagnosis and treatment of scabies, head lice, and bed bugs."},{"mesh_descriptors":[],"pmid":"30828591","title":"Effect of a New Head Lice Treatment, Abametapir Lotion, 0.74%, on Louse Eggs: A Randomized, Double-Blind Study."},{"mesh_descriptors":[],"pmid":"40309371","title":"Abametapir: A New Solution to an Age Old Problem."},{"mesh_descriptors":[{"qualifiers":["analogs &amp; derivatives"],"descriptor":"2,2'-Dipyridyl"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Dose-Response Relationship, Drug"},{"qualifiers":[],"descriptor":"Insect Control"},{"qualifiers":[],"descriptor":"Insecticides"},{"qualifiers":["growth &amp; development"],"descriptor":"Ovum"},{"qualifiers":["growth &amp; development"],"descriptor":"Pediculus"}],"pmid":"28082644","title":"Ovicidal Efficacy of Abametapir Against Eggs of Human Head and Body Lice (Anoplura: Pediculidae)."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["pharmacology"],"descriptor":"Insecticides"},{"qualifiers":["prevention &amp; control"],"descriptor":"Lice Infestations"},{"qualifiers":["genetics"],"descriptor":"Pediculus"}],"pmid":"35082036","title":"New chemistries for the control of human head lice, Pediculus humanus capitis: A mini-review."}],"translation_set":[],"indication":"Abametapir is indicated, in the context of an overall lice management program, for the topical treatment of head lice infestation in patients 6 months of age and older.[L15153]","status":"success","count":10,"disease_analysis":{"summary":{"unique_diseases_found":3,"matched_diseases":["Scalp Dermatoses","Scabies","Lice Infestations"],"diseases_with_associations":3,"total_mesh_terms":61,"total_publications_analyzed":10},"disease_associations":{"Scalp Dermatoses":[{"pmid":"38905531","title":"Drugs for head lice.","qualifiers":["drug therapy"]},{"pmid":"29999197","title":"Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation.","qualifiers":["drug therapy"]}],"Scabies":[{"pmid":"34074914","title":"Common pediatric infestations: update on diagnosis and treatment of scabies, head lice, and bed bugs.","qualifiers":["diagnosis","drug therapy","epidemiology"]}],"Lice Infestations":[{"pmid":"38905531","title":"Drugs for head lice.","qualifiers":["drug therapy"]},{"pmid":"34157881","title":"Abametapir for the Treatment of Head Lice: A Drug Review.","qualifiers":["drug therapy"]},{"pmid":"29999197","title":"Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation.","qualifiers":["drug therapy"]},{"pmid":"35839355","title":"Abametapir 0.74% (Xeglyze) for the Treatment of Head Lice.","qualifiers":["drug therapy"]},{"pmid":"34074914","title":"Common pediatric infestations: update on diagnosis and treatment of scabies, head lice, and bed bugs.","qualifiers":["diagnosis","drug therapy","epidemiology"]},{"pmid":"35082036","title":"New chemistries for the control of human head lice, Pediculus humanus capitis: A mini-review.","qualifiers":["prevention &amp; control"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abametapir%22%5BTIAB%5D%20OR%20%22Abametapir%22%5BMeSH%20Terms%5D","original_query":"\"Abametapir\"[TIAB] OR \"Abametapir\"[MeSH Terms]","retmax":10,"query":"\"Abametapir\"[TIAB] OR \"Abametapir\"[MeSH Terms]","pmids":["38905531","34157881","36552044","29999197","35839355","34074914","30828591","40309371","28082644","35082036"]},{"query_translation":"\"Abarelix\"[Title/Abstract]","search_time":"2025-06-29T09:09:38.038","drug_name":"Abarelix","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Antineoplastic Agents"},{"qualifiers":[],"descriptor":"Clinical Trials as Topic"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Drugs, Investigational"},{"qualifiers":["drug therapy"],"descriptor":"Endometriosis"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Estrogen Antagonists"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Oligopeptides"},{"qualifiers":["drug therapy"],"descriptor":"Prostatic Neoplasms"}],"pmid":"12757402","title":"Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827."},{"mesh_descriptors":[{"qualifiers":["administration &amp; dosage","adverse effects","pharmacology"],"descriptor":"Antineoplastic Agents, Hormonal"},{"qualifiers":[],"descriptor":"Delayed-Action Preparations"},{"qualifiers":["agonists","antagonists &amp; inhibitors"],"descriptor":"Gonadotropin-Releasing Hormone"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["administration &amp; dosage","adverse effects","pharmacology"],"descriptor":"Oligopeptides"},{"qualifiers":["administration &amp; dosage","adverse effects","pharmacology"],"descriptor":"Phenylurea Compounds"},{"qualifiers":["drug therapy","pathology"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":["administration &amp; dosage","adverse effects","pharmacology"],"descriptor":"Pyrimidinones"}],"pmid":"28870102","title":"Therapeutic outcomes of the LHRH antagonists."},{"mesh_descriptors":[{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Agents, Hormonal"},{"qualifiers":[],"descriptor":"Clinical Trials, Phase II as Topic"},{"qualifiers":[],"descriptor":"Clinical Trials, Phase III as Topic"},{"qualifiers":[],"descriptor":"Drug-Related Side Effects and Adverse Reactions"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Gonadotropin-Releasing Hormone"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["pharmacokinetics","pharmacology","therapeutic use"],"descriptor":"Oligopeptides"},{"qualifiers":["drug therapy"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"17155895","title":"Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer."},{"mesh_descriptors":[{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Androgen Antagonists"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Antineoplastic Agents, Hormonal"},{"qualifiers":[],"descriptor":"Epidemiologic Methods"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Gonadotropin-Releasing Hormone"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Oligopeptides"},{"qualifiers":["drug therapy"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"20053189","title":"Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["therapeutic use"],"descriptor":"Androgen Antagonists"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Agents, Hormonal"},{"qualifiers":[],"descriptor":"Delayed-Action Preparations"},{"qualifiers":["blood"],"descriptor":"Dihydrotestosterone"},{"qualifiers":["blood"],"descriptor":"Follicle Stimulating Hormone"},{"qualifiers":["agonists","antagonists &amp; inhibitors"],"descriptor":"Gonadotropin-Releasing Hormone"},{"qualifiers":["therapeutic use"],"descriptor":"Goserelin"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Injections, Intramuscular"},{"qualifiers":["therapeutic use"],"descriptor":"Leuprolide"},{"qualifiers":["blood"],"descriptor":"Luteinizing Hormone"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Oligopeptides"},{"qualifiers":[],"descriptor":"Prospective Studies"},{"qualifiers":["blood"],"descriptor":"Prostate-Specific Antigen"},{"qualifiers":["blood","diagnosis","drug therapy"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":["drug effects"],"descriptor":"Testis"},{"qualifiers":["blood"],"descriptor":"Testosterone"}],"pmid":"11342922","title":"The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":[],"descriptor":"Drug Therapy"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Randomized Controlled Trials as Topic"}],"pmid":"12092009","title":"Gateways to clinical trials."},{"mesh_descriptors":[{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Antineoplastic Agents, Hormonal"},{"qualifiers":["agonists","antagonists &amp; inhibitors"],"descriptor":"Gonadotropin-Releasing Hormone"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Leuprolide"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Oligopeptides"},{"qualifiers":["blood"],"descriptor":"Prostate-Specific Antigen"},{"qualifiers":["blood","drug therapy"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":["blood"],"descriptor":"Testosterone"}],"pmid":"22416801","title":"Gonadotropin-releasing hormone: an update review of the antagonists versus agonists."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Androgen Antagonists"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Goserelin"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Leuprolide"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Oligopeptides"},{"qualifiers":[],"descriptor":"Prospective Studies"},{"qualifiers":["metabolism"],"descriptor":"Prostate-Specific Antigen"},{"qualifiers":["blood","drug therapy"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":["antagonists &amp; inhibitors","metabolism"],"descriptor":"Testosterone"},{"qualifiers":[],"descriptor":"United States"}],"pmid":"22093775","title":"New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist."},{"mesh_descriptors":[{"qualifiers":["economics","therapeutic use"],"descriptor":"Antineoplastic Agents"},{"qualifiers":[],"descriptor":"Cost-Benefit Analysis"},{"qualifiers":[],"descriptor":"Disease Progression"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Gonadotropin-Releasing Hormone"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Neoplasm Staging"},{"qualifiers":["economics","therapeutic use"],"descriptor":"Oligopeptides"},{"qualifiers":["drug therapy","pathology"],"descriptor":"Prostatic Neoplasms"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Testosterone"}],"pmid":"24775720","title":"Utility of LHRH antagonists for advanced prostate cancer."},{"mesh_descriptors":[],"pmid":"16986005","title":"Emerging pharmacologic therapies for prostate cancer."}],"translation_set":[],"indication":"For palliative treatment of advanced prostate cancer.","status":"success","count":55,"disease_analysis":{"summary":{"unique_diseases_found":2,"matched_diseases":["Drug-Related Side Effects and Adverse Reactions","Endometriosis"],"diseases_with_associations":2,"total_mesh_terms":98,"total_publications_analyzed":10},"disease_associations":{"Drug-Related Side Effects and Adverse Reactions":[{"pmid":"17155895","title":"Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.","qualifiers":[]}],"Endometriosis":[{"pmid":"12757402","title":"Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827.","qualifiers":["drug therapy"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abarelix%22%5BTIAB%5D%20OR%20%22Abarelix%22%5BMeSH%20Terms%5D","original_query":"\"Abarelix\"[TIAB] OR \"Abarelix\"[MeSH Terms]","retmax":10,"query":"\"Abarelix\"[TIAB] OR \"Abarelix\"[MeSH Terms]","pmids":["12757402","28870102","17155895","20053189","11342922","12092009","22416801","22093775","24775720","16986005"]},{"query_translation":"\"Abatacept\"[Title/Abstract] OR \"Abatacept\"[MeSH Terms]","search_time":"2025-06-29T09:09:38.73","drug_name":"Abatacept","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":[],"descriptor":"Administration, Oral"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Antirheumatic Agents"},{"qualifiers":["blood","drug therapy"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":["analysis"],"descriptor":"C-Reactive Protein"},{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":[],"descriptor":"Drug Tolerance"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Heterocyclic Compounds, 3-Ring"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Inducible T-Cell Co-Stimulator Protein"},{"qualifiers":[],"descriptor":"Infusions, Intravenous"},{"qualifiers":[],"descriptor":"Intention to Treat Analysis"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Janus Kinase Inhibitors"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Remission Induction"}],"pmid":"33053283","title":"Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy"],"descriptor":"Myocarditis"},{"qualifiers":["therapeutic use"],"descriptor":"Immune Checkpoint Inhibitors"},{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Agents, Immunological"},{"qualifiers":["complications","drug therapy"],"descriptor":"Myotoxicity"},{"qualifiers":["drug therapy","complications","pathology"],"descriptor":"Myositis"},{"qualifiers":["pathology"],"descriptor":"Respiratory Muscles"}],"pmid":"36815259","title":"Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["genetics"],"descriptor":"CTLA-4 Antigen"},{"qualifiers":["therapeutic use"],"descriptor":"Immunosuppressive Agents"},{"qualifiers":[],"descriptor":"Autoimmunity"},{"qualifiers":[],"descriptor":"Hematopoietic Stem Cell Transplantation"},{"qualifiers":[],"descriptor":"Adaptor Proteins, Signal Transducing"}],"pmid":"37595759","title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Certolizumab Pegol"},{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["adverse effects"],"descriptor":"Antirheumatic Agents"},{"qualifiers":["diagnostic imaging","drug therapy","chemically induced"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":["therapeutic use"],"descriptor":"Methotrexate"},{"qualifiers":[],"descriptor":"Drug Therapy, Combination"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"37423647","title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial."},{"mesh_descriptors":[{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["therapeutic use"],"descriptor":"Anti-Citrullinated Protein Antibodies"},{"qualifiers":["therapeutic use"],"descriptor":"Antirheumatic Agents"},{"qualifiers":["complications","drug therapy"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["complications","drug therapy"],"descriptor":"Lung Diseases, Interstitial"}],"pmid":"35121155","title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease."},{"mesh_descriptors":[{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["therapeutic use"],"descriptor":"Antirheumatic Agents"},{"qualifiers":["chemically induced","drug therapy"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Fibrosis"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["pharmacology","therapeutic use"],"descriptor":"Janus Kinase Inhibitors"},{"qualifiers":["chemically induced","complications","drug therapy"],"descriptor":"Lung Diseases, Interstitial"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Retrospective Studies"}],"pmid":"35462572","title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use","pharmacology"],"descriptor":"Abatacept"},{"qualifiers":["drug therapy"],"descriptor":"Diabetes Mellitus, Type 1"},{"qualifiers":[],"descriptor":"Immunosuppressive Agents"},{"qualifiers":[],"descriptor":"T-Lymphocytes, Regulatory"},{"qualifiers":["therapeutic use"],"descriptor":"Glucose"}],"pmid":"36920087","title":"Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy","prevention &amp; control"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":["therapeutic use"],"descriptor":"Antirheumatic Agents"},{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["therapeutic use"],"descriptor":"Rituximab"},{"qualifiers":[],"descriptor":"Autoimmunity"}],"pmid":"36280095","title":"Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adolescent"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects"],"descriptor":"Abatacept"},{"qualifiers":[],"descriptor":"Arthralgia"},{"qualifiers":["drug therapy"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":[],"descriptor":"Pain"},{"qualifiers":[],"descriptor":"Rheumatoid Factor"},{"qualifiers":[],"descriptor":"Synovitis"}],"pmid":"38364839","title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial."},{"mesh_descriptors":[{"qualifiers":["therapeutic use"],"descriptor":"Abatacept"},{"qualifiers":["therapeutic use"],"descriptor":"Antirheumatic Agents"},{"qualifiers":["chemically induced","drug therapy"],"descriptor":"Arthritis, Rheumatoid"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Interleukin-6"},{"qualifiers":["therapeutic use"],"descriptor":"Janus Kinase Inhibitors"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":[],"descriptor":"Tumor Necrosis Factor Inhibitors"},{"qualifiers":[],"descriptor":"Tumor Necrosis Factor-alpha"}],"pmid":"35705376","title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration."}],"translation_set":[],"indication":"Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and in patients ≥2 years of age for the treatment of active psoriatic arthritis.[L48811] In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.[L20504] Abatacept is also indicated for the prophylaxis of acute graft-versus-host disease, in combination with [methotrexate] and a calcineurin inhibitor such as [tacrolimus], in patients two years of age and older who are undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.[L20504]","status":"success","count":4830,"disease_analysis":{"summary":{"unique_diseases_found":6,"matched_diseases":["Myocarditis","Synovitis","Myositis","Arthritis, Rheumatoid","Diabetes Mellitus, Type 1","Lung Diseases, Interstitial"],"diseases_with_associations":6,"total_mesh_terms":86,"total_publications_analyzed":10},"disease_associations":{"Myocarditis":[{"pmid":"36815259","title":"Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.","qualifiers":["drug therapy"]}],"Synovitis":[{"pmid":"38364839","title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.","qualifiers":[]}],"Myositis":[{"pmid":"36815259","title":"Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.","qualifiers":["drug therapy","complications","pathology"]}],"Arthritis, Rheumatoid":[{"pmid":"33053283","title":"Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.","qualifiers":["blood","drug therapy"]},{"pmid":"37423647","title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.","qualifiers":["diagnostic imaging","drug therapy","chemically induced"]},{"pmid":"35121155","title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.","qualifiers":["complications","drug therapy"]},{"pmid":"35462572","title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.","qualifiers":["chemically induced","drug therapy"]},{"pmid":"36280095","title":"Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals.","qualifiers":["drug therapy","prevention &amp; control"]},{"pmid":"38364839","title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.","qualifiers":["drug therapy"]},{"pmid":"35705376","title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.","qualifiers":["chemically induced","drug therapy"]}],"Diabetes Mellitus, Type 1":[{"pmid":"36920087","title":"Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.","qualifiers":["drug therapy"]}],"Lung Diseases, Interstitial":[{"pmid":"35121155","title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.","qualifiers":["complications","drug therapy"]},{"pmid":"35462572","title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.","qualifiers":["chemically induced","complications","drug therapy"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abatacept%22%5BTIAB%5D%20OR%20%22Abatacept%22%5BMeSH%20Terms%5D","original_query":"\"Abatacept\"[TIAB] OR \"Abatacept\"[MeSH Terms]","retmax":10,"query":"\"Abatacept\"[TIAB] OR \"Abatacept\"[MeSH Terms]","pmids":["33053283","36815259","37595759","37423647","35121155","35462572","36920087","36280095","38364839","35705376"]},{"query_translation":"\"Abciximab\"[Title/Abstract] OR \"Abciximab\"[MeSH Terms]","search_time":"2025-06-29T09:09:39.485","drug_name":"Abciximab","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":["pharmacology"],"descriptor":"Abciximab"},{"qualifiers":[],"descriptor":"Amino Acid Sequence"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["drug effects","metabolism"],"descriptor":"Blood Platelets"},{"qualifiers":["pharmacology"],"descriptor":"Eptifibatide"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Molecular Targeted Therapy"},{"qualifiers":["pharmacology"],"descriptor":"Platelet Aggregation Inhibitors"},{"qualifiers":["agonists","antagonists &amp; inhibitors","metabolism"],"descriptor":"Platelet Glycoprotein GPIIb-IIIa Complex"},{"qualifiers":[],"descriptor":"Signal Transduction"},{"qualifiers":["pharmacology"],"descriptor":"Tirofiban"}],"pmid":"30845955","title":"Platelet integrin &#x3b1;IIb&#x3b2;3: signal transduction, regulation, and its therapeutic targeting."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":[],"descriptor":"Anticoagulants"},{"qualifiers":[],"descriptor":"Heart-Assist Devices"},{"qualifiers":[],"descriptor":"Heparin"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Thrombocytopenia"}],"pmid":"29371038","title":"Reply."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":[],"descriptor":"Angioplasty, Balloon, Coronary"},{"qualifiers":["therapeutic use"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":["therapeutic use"],"descriptor":"Antithrombins"},{"qualifiers":["drug therapy","therapy"],"descriptor":"Coronary Disease"},{"qualifiers":[],"descriptor":"Eptifibatide"},{"qualifiers":["therapeutic use"],"descriptor":"Heparin"},{"qualifiers":[],"descriptor":"Hirudins"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":["therapeutic use"],"descriptor":"Peptide Fragments"},{"qualifiers":["therapeutic use"],"descriptor":"Peptides"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Platelet Glycoprotein GPIIb-IIIa Complex"},{"qualifiers":[],"descriptor":"Randomized Controlled Trials as Topic"},{"qualifiers":["therapeutic use"],"descriptor":"Recombinant Proteins"}],"pmid":"15987622","title":"Direct thrombin inhibitors."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects"],"descriptor":"Abciximab"},{"qualifiers":["therapeutic use"],"descriptor":"Platelet Aggregation Inhibitors"},{"qualifiers":[],"descriptor":"Platelet Glycoprotein GPIIb-IIIa Complex"},{"qualifiers":["therapeutic use"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":["adverse effects"],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":[],"descriptor":"Tyrosine"},{"qualifiers":["chemically induced"],"descriptor":"Thrombocytopenia"}],"pmid":"38063187","title":"Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":["therapeutic use"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":[],"descriptor":"Clinical Trials as Topic"},{"qualifiers":["drug therapy"],"descriptor":"Coronary Disease"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":["therapeutic use"],"descriptor":"Platelet Aggregation Inhibitors"}],"pmid":"12587933","title":"Abciximab: IIb or not IIb, is that still the question?"},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Adenosine Monophosphate"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":[],"descriptor":"Shock, Cardiogenic"}],"pmid":"29217012","title":"Cangrelor or Abciximab as&#xa0;First Choice in Cardiogenic Shock."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":["mortality","therapy"],"descriptor":"Acute Coronary Syndrome"},{"qualifiers":["methods"],"descriptor":"Angioplasty, Balloon, Coronary"},{"qualifiers":["therapeutic use"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":["therapeutic use"],"descriptor":"Anticoagulants"},{"qualifiers":[],"descriptor":"Chemotherapy, Adjuvant"},{"qualifiers":["chemically induced"],"descriptor":"Hemorrhage"},{"qualifiers":[],"descriptor":"Hirudins"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":["therapeutic use"],"descriptor":"Peptide Fragments"},{"qualifiers":["therapeutic use"],"descriptor":"Platelet Aggregation Inhibitors"},{"qualifiers":[],"descriptor":"Randomized Controlled Trials as Topic"},{"qualifiers":["therapeutic use"],"descriptor":"Recombinant Proteins"},{"qualifiers":[],"descriptor":"Regression Analysis"},{"qualifiers":[],"descriptor":"Tirofiban"},{"qualifiers":["analogs &amp; derivatives","therapeutic use"],"descriptor":"Tyrosine"}],"pmid":"19755402","title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":["blood","drug therapy"],"descriptor":"Acute Coronary Syndrome"},{"qualifiers":["therapeutic use"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":["drug effects"],"descriptor":"Blood Coagulation"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":["therapeutic use"],"descriptor":"Platelet Aggregation Inhibitors"},{"qualifiers":[],"descriptor":"Treatment Outcome"}],"pmid":"27519521","title":"How abciximab might be clinically useful."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Adenosine Monophosphate"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Immunoglobulin Fab Fragments"},{"qualifiers":[],"descriptor":"Shock, Cardiogenic"}],"pmid":"29217013","title":"Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["metabolism"],"descriptor":"Platelet Glycoprotein GPIIb-IIIa Complex"},{"qualifiers":[],"descriptor":"Abciximab"},{"qualifiers":["pharmacology"],"descriptor":"Tirofiban"},{"qualifiers":[],"descriptor":"Eptifibatide"},{"qualifiers":["pharmacology","therapeutic use"],"descriptor":"Peptides"},{"qualifiers":["drug therapy","metabolism"],"descriptor":"Thrombosis"},{"qualifiers":[],"descriptor":"Signal Transduction"}],"pmid":"36380406","title":"Anti-Platelet Peptides Targeting &#x3b1;IIb&#x3b2;3 Outside-In Signaling Pathway."}],"translation_set":[],"indication":"Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.","status":"success","count":2778,"disease_analysis":{"summary":{"unique_diseases_found":3,"matched_diseases":["Coronary Disease","Thrombocytopenia","Acute Coronary Syndrome"],"diseases_with_associations":3,"total_mesh_terms":90,"total_publications_analyzed":10},"disease_associations":{"Coronary Disease":[{"pmid":"15987622","title":"Direct thrombin inhibitors.","qualifiers":["drug therapy","therapy"]},{"pmid":"12587933","title":"Abciximab: IIb or not IIb, is that still the question?","qualifiers":["drug therapy"]}],"Thrombocytopenia":[{"pmid":"29371038","title":"Reply.","qualifiers":[]},{"pmid":"38063187","title":"Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s).","qualifiers":["chemically induced"]}],"Acute Coronary Syndrome":[{"pmid":"19755402","title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.","qualifiers":["mortality","therapy"]},{"pmid":"27519521","title":"How abciximab might be clinically useful.","qualifiers":["blood","drug therapy"]}]}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abciximab%22%5BTIAB%5D%20OR%20%22Abciximab%22%5BMeSH%20Terms%5D","original_query":"\"Abciximab\"[TIAB] OR \"Abciximab\"[MeSH Terms]","retmax":10,"query":"\"Abciximab\"[TIAB] OR \"Abciximab\"[MeSH Terms]","pmids":["30845955","29371038","15987622","38063187","12587933","29217012","19755402","27519521","29217013","36380406"]},{"query_translation":"\"Abemaciclib\"[Title/Abstract]","search_time":"2025-06-29T09:09:40.235","drug_name":"Abemaciclib","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Aminopyridines"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Antineoplastic Agents, Hormonal"},{"qualifiers":["adverse effects","therapeutic use"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Benzimidazoles"},{"qualifiers":["drug therapy","metabolism","pathology"],"descriptor":"Breast Neoplasms"},{"qualifiers":[],"descriptor":"Chemotherapy, Adjuvant"},{"qualifiers":[],"descriptor":"Disease-Free Survival"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Lymphatic Metastasis"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["pathology"],"descriptor":"Neoplasm Recurrence, Local"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Protein Kinase Inhibitors"},{"qualifiers":["metabolism"],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["metabolism"],"descriptor":"Receptors, Estrogen"},{"qualifiers":["metabolism"],"descriptor":"Receptors, Progesterone"},{"qualifiers":[],"descriptor":"Young Adult"}],"pmid":"32954927","title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Aminopyridines"},{"qualifiers":[],"descriptor":"Anastrozole"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Aromatase Inhibitors"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Benzimidazoles"},{"qualifiers":[],"descriptor":"Biomarkers, Tumor"},{"qualifiers":["drug therapy"],"descriptor":"Breast Neoplasms"},{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Letrozole"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Nitriles"},{"qualifiers":[],"descriptor":"Postmenopause"},{"qualifiers":[],"descriptor":"Receptor, ErbB-2"},{"qualifiers":[],"descriptor":"Survival Rate"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Triazoles"}],"pmid":"28968163","title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Aminopyridines"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Benzimidazoles"},{"qualifiers":["drug therapy","enzymology","metabolism"],"descriptor":"Breast Neoplasms"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Cyclin-Dependent Kinase 4"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Cyclin-Dependent Kinase 6"},{"qualifiers":[],"descriptor":"Disease-Free Survival"},{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":["administration &amp; dosage","analogs &amp; derivatives","therapeutic use"],"descriptor":"Estradiol"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Fulvestrant"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["biosynthesis"],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["biosynthesis"],"descriptor":"Receptors, Estrogen"},{"qualifiers":["biosynthesis"],"descriptor":"Receptors, Progesterone"}],"pmid":"28580882","title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Adolescent"},{"qualifiers":["drug therapy","genetics","metabolism"],"descriptor":"Breast Neoplasms"},{"qualifiers":["adverse effects"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["pathology"],"descriptor":"Neoplasm Recurrence, Local"},{"qualifiers":["metabolism"],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["etiology"],"descriptor":"Diarrhea"}],"pmid":"36493792","title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Aminopyridines"},{"qualifiers":["therapeutic use","administration &amp; dosage"],"descriptor":"Anastrozole"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["therapeutic use","administration &amp; dosage"],"descriptor":"Aromatase Inhibitors"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Benzimidazoles"},{"qualifiers":["drug therapy","pathology","mortality"],"descriptor":"Breast Neoplasms"},{"qualifiers":[],"descriptor":"Double-Blind Method"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Letrozole"},{"qualifiers":[],"descriptor":"Progression-Free Survival"},{"qualifiers":["metabolism","antagonists &amp; inhibitors"],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["metabolism"],"descriptor":"Receptors, Estrogen"},{"qualifiers":["metabolism"],"descriptor":"Receptors, Progesterone"}],"pmid":"38729566","title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Aminopyridines"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Benzimidazoles"},{"qualifiers":["drug therapy","genetics","mortality","pathology"],"descriptor":"Breast Neoplasms"},{"qualifiers":["analysis","antagonists &amp; inhibitors","genetics","metabolism"],"descriptor":"Estrogen Receptor alpha"},{"qualifiers":[],"descriptor":"Mutation"},{"qualifiers":[],"descriptor":"Progression-Free Survival"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Benzopyrans"},{"qualifiers":["analysis"],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["administration &amp; dosage","adverse effects"],"descriptor":"Fulvestrant"},{"qualifiers":["drug therapy","mortality","pathology"],"descriptor":"Breast Neoplasms, Male"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":[],"descriptor":"Androstadienes"}],"pmid":"39660834","title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["drug therapy"],"descriptor":"Breast Neoplasms"},{"qualifiers":[],"descriptor":"Neoplasm Recurrence, Local"},{"qualifiers":[],"descriptor":"Adjuvants, Immunologic"},{"qualifiers":[],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["adverse effects"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":[],"descriptor":"Aminopyridines"},{"qualifiers":[],"descriptor":"Benzimidazoles"}],"pmid":"38194616","title":"Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aminopyridines"},{"qualifiers":["adverse effects"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":[],"descriptor":"Benzimidazoles"},{"qualifiers":["metabolism"],"descriptor":"Breast Neoplasms"},{"qualifiers":["drug therapy"],"descriptor":"Diarrhea"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy"],"descriptor":"Neoplasm Recurrence, Local"},{"qualifiers":[],"descriptor":"Patient Reported Outcome Measures"},{"qualifiers":[],"descriptor":"Quality of Life"},{"qualifiers":["metabolism"],"descriptor":"Receptor, ErbB-2"}],"pmid":"35337972","title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study."},{"mesh_descriptors":[{"qualifiers":["adverse effects"],"descriptor":"Aminopyridines"},{"qualifiers":["adverse effects"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":[],"descriptor":"Benzimidazoles"},{"qualifiers":["pathology"],"descriptor":"Breast Neoplasms"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Fulvestrant"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Receptor, ErbB-2"},{"qualifiers":["drug therapy"],"descriptor":"Triple Negative Breast Neoplasms"}],"pmid":"31563959","title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aminopyridines"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":[],"descriptor":"Benzimidazoles"},{"qualifiers":["drug therapy"],"descriptor":"Breast Neoplasms"},{"qualifiers":[],"descriptor":"Chemotherapy, Adjuvant"},{"qualifiers":[],"descriptor":"Disease-Free Survival"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Ki-67 Antigen"},{"qualifiers":["drug therapy"],"descriptor":"Neoplasm Recurrence, Local"},{"qualifiers":[],"descriptor":"Receptor, ErbB-2"}],"pmid":"34656740","title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study."}],"translation_set":[],"indication":"* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","status":"success","count":1125,"disease_analysis":{"summary":{"unique_diseases_found":0,"matched_diseases":[],"diseases_with_associations":0,"total_mesh_terms":149,"total_publications_analyzed":10},"disease_associations":{}},"original_url":"https://pubmed.ncbi.nlm.nih.gov/?term=%22Abemaciclib%22%5BTIAB%5D%20OR%20%22Abemaciclib%22%5BMeSH%20Terms%5D","original_query":"\"Abemaciclib\"[TIAB] OR \"Abemaciclib\"[MeSH Terms]","retmax":10,"query":"\"Abemaciclib\"[TIAB] OR \"Abemaciclib\"[MeSH Terms]","pmids":["32954927","28968163","28580882","36493792","38729566","39660834","38194616","35337972","31563959","34656740"]}]